TAmiRNA is hiring
We cannot wait to meet you to share our passion in Transcriptomics! Interested candidates should email a cover letter and resume to karriere@tamirna.com Click here to read the job description
16
01, 2025
9
01, 2025
TAmiRNA ‘2024 In Review’TAmiRNA ‘2024 In Review’
biomarker, Biomarker Discovery, biomarkers, CE-IVD, congress, EVscale, exosomes, extracellular vesicle, hepatomiR kit, Illumina NewSeq2000, ISO 13485, liquid biopsies, Liver disease, microRNA, microRNA services, microRNAs, NGS, PCR testing service, quality, sequencing, small RNA-sequencing, smallRNA, test service
TAmiRNA ‘2024 In Review’
2024: A Year of Growth, Innovation, and Collaboration 2024 has come to a close. We are proud to reflect on the milestones and achievements we’ve reached together with our incredible team, customers, partners, and supporters. Here’s a look back at what we accomplished this year: 👩🔬 Team Expansion Welcomed 3 talented new members to our growing team. 🏥 Diagnostic Implementation Successfully rolled out our CE-IVD microRNA liver function test in 5+ clinics, advancing molecular diagnostics. ✅ Service Excellence Completed over 80 RNA service projects, achieving 100% customer satisfaction. 🛠 Bioinformatics Innovation Developed 2 new pipelines: isomiR analysis and tRNA analysis, enhancing our capabilities. 🧬 Expanded Service Offerings Added whole-transcriptome sequencing for mRNA, lncRNA, and circRNA in liquid biopsies to our service portfolio. [...]
11
12, 2024
TAmiRNA at SURGER-I Innsbruck Congress 2024
We are thrilled to announce that TAmiRNA will participate in the SURGER-I Innsbruck Congress on December 12–13, 2024. This premier event brings together leading experts, researchers, and practitioners to explore advancements in hepatopancreatobiliary surgery and transplantation. As a proud sponsor, we will showcase our hepatomiR® kit, the first CE-IVD microRNA biomarker for the pre-operative assessment of liver function. Attendees can find us featured in the final program and on an intermission slide during the event. We are also delighted to share that Dr. Matthias Hackl, CEO/CSO of TAmiRNA, will be attending the conference. This provides an excellent opportunity to connect and learn about our latest clinical trial data, as well as how hepatomiR® can be implemented in [...]
22
10, 2024
Webinar Announcement
🔬 Join us for an insightful webinar on transcriptomics where we will delve into cutting-edge strategies for biomarker discovery, basic research, and translational applications. Whether you're focused on diagnostics or overcoming the challenges of low-input sample analysis, this webinar is designed for you! Title: Harnessing Transcriptomics: microRNA and mRNA analysis for Biomarker Discovery, Basic Research, and Translational Applications What to Expect: Comprehensive Transcriptomics Sequencing Services tailored to your research needs Insights into Biomarker Discovery, driving breakthrough advancements in diagnostics Strategies to overcome challenges with low-input samples, including biofluids and extracellular vesicles Opportunity to connect with our experts to discuss your transcriptomics goals and potential collaborations 📅 Date: 7.11.2024 🕒 Time: 14:00 -15:00 CET Presentation by Matthias Hackl, [...]
17
10, 2024
TAmiRNA at Precision EV Forum in Cambridge
Excited to share that TAmiRNA and Evercyte will join forces at the upcoming Precision EV Forum in Cambridge! 🚀 As key members of the EVscale® consortium, they’ll be showcasing cutting-edge solutions in EV (extracellular vesicles) characterization and therapeutics. TAmiRNA will present its advanced multiomic capabilities for RNA cargo characterization, aiding in biomarker discovery. Evercyte will highlight its clinical-grade EVs produced from telomerized MSCs, demonstrating the potential of EV therapeutics. Together with Phoenestra's bioreactor technology, these innovations support faster, scalable EV production. 🌱🧬 Catch us at Cripps Court Conference Centre and discover our vision for the future of EV-based precision medicine! 💡🔬 Meet us at the Precision EV Forum or reach out to info@tamirna.com to discuss our latest [...]
15
10, 2024
Eager to lern more about differential miRNA expression patterns in Type 2 diabetes mellitusEager to lern more about differential miRNA expression patterns in Type 2 diabetes mellitus
biomarker, bone diseases, bone fracture risk assessment, diabetes, microRNA services, microRNAs, miND spike ins, NGS, sequencing, smallRNA
Eager to lern more about differential miRNA expression patterns in Type 2 diabetes mellitus
Excited to share our latest study on the link between Type 2 Diabetes Mellitus (T2DM) and bone fragility using miRNA profiling in a polygenic mouse model! 🧬🦴 🔍 Research Highlights: We utilized an unbiased genome-wide approach to identify dysregulated miRNAs in serum, bone marrow, and bone of the TallyHo/JngJ (TH) mouse model, which closely mirrors T2DM in humans. Key findings include upregulation of miRNAs such as mmu-miR-466i-5p and mmu-miR-1195 in both serum and bone marrow of diabetic mice. Dysregulated miRNAs were linked to pathways associated with diabetes-related signaling and diabetic bone disease, shedding light on potential mechanistic pathways. Cell-type enrichment analysis pointed towards miRNAs enriched in specific cell types like immune cells, hepatocytes, and mesenchymal stem cells, [...]
7
10, 2024
Celebrating the Nobel Prize in Physiology or Medicine 2024!
Congratulations to Victor Ambros and Gary Ruvkun, this year’s Nobel Laureates, for their pioneering discovery of microRNAs—tiny but powerful molecules that regulate gene expression and have reshaped our understanding of biology, aging, cancer, and development. At TAmiRNA, we’ve been deeply inspired by this breakthrough and have dedicated over 10 years to harnessing the potential of microRNAs. We’ve developed cutting-edge diagnostic tools that leverage microRNAs as biomarkers, with our regulatory approved hepatomiR® device leading the way in improving liver cancer patient care across Europe. Our passion for innovation has resulted in over 100 scientific publications, and we’re proud to contribute to advancing this transformative field. The Nobel Prize serves as a reminder of the impact that these discoveries can [...]
27
09, 2024
TAmiRNA at the GSEV 2024 Scientific Conference
We are thrilled to announce that TAmiRNA will contribute a poster at the upcoming German Society for Extracellular Vesicles (GSEV) Autumn Meeting 2024, presenting our recent advancements in the biodistribution of extracellular vesicles (EVs). The poster will be presented by our expert, Magdalena Mecking. Don’t miss this opportunity to explore TAmiRNA's latest advancements regarding transcriptomic characterization of EVs. Meet Magdalena at the GSEV or reach out to info@tamirna.com to discuss our latest developments and how TAmiRNA’s services for EV characterization can assist your business! Click here to read the press release. TAmiRNA Scientific Consultant Magdalena Mecking
18
09, 2024
Eager to lern more about neuron-derived extracellular vesicles as predictive biomarkers
A new study from the University of Trieste explores the potential of microRNA (miRNA) profiles in neuron-derived extracellular vesicles (NDEVs) as predictive biomarkers for adverse drug reactions (ADRs) in children receiving ketamine. This research, leveraging TAmiRNA's Next-Generation Sequencing (NGS)-based miND® pipeline, identified specific miRNAs (miR-18a-3p, miR-484, and miR-548az-5p) as potential tools to predict ketamine-induced ADRs. This breakthrough not only advances our understanding of ketamine's side effects in children but also demonstrates the biomarker potential of organ-specific EVs and their miRNA cargo. Interested in our of extracellular vesicles (EVs) and exosomes services - click here! click here to read the paper
11
09, 2024
TAmiRNA at ASEV/CzeSEV meeting
TAmiRNA, Evercyte and Phoenestra, three leading biotech companies, will present their cutting-edge work in for production and characterization of clinical-grade extracellular vesicles (EVs) at the upcoming shared Annual Meeting of the Austrian and Czechia Societies for Extracellular Vesicles (ASEV & CzeSEV) on 16th/17th September in Vienna. As esteemed ASEV members, TAmiRNA and Evercyte are well-known participants at these meetings and this year will take the spotlight as Platinum Sponsors. They will be joined by Phoenestra in this sponsorship as part of the EVscale™ Partnership, showcasing their joint capabilities and innovation in EV research and development. Don’t miss this opportunity to explore TAmiRNA's latest advancements regarding transcriptomic characterization of EVs. Meet us at the ASEV or reach out to [...]